Trial Profile
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Dec 2020
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Merkel cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 1 Jul 2020 to 1 Sep 2020.
- 09 Jan 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Sep 2019.